Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of Multiple Ascending Dose (MAD) of PA1010 Tablets in Chinese Patients With Chronic Hepatitis B Infection

NCT05019040 is registered in ClinicalTrials.gov with Zhejiang Palo Alto Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05019040
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05019040 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of Multiple Ascending Dose (MAD) of PA1010 Tablets in Chinese Patients With Chronic Hepatitis B Infection
Lead sponsor
Zhejiang Palo Alto Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
September 17, 2021
Completion date
November 18, 2022
Enrollment
36 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hbv infection